Literature DB >> 7835004

Clinical correlation of anticentromere antibodies.

M Zuber1, R Gotzen, I Filler.   

Abstract

A retrospective survey of all patients with a positive anticentromere antibody (ACA) determination was undertaken over a 3-years period of time in a university hospital. Forty-five patients were positive for anticentromere antibodies. The analysis of the clinical characteristics and diagnoses of the patients with anticentromere antibodies were correlated and showed a diverse array of symptoms. Only 4.4% had CREST syndrome, 6.7% had limited scleroderma, 17.8% had diffuse scleroderma, 20% had other connective tissue diseases, 20% had other miscellaneous rheumatic conditions, 11.1% had tumours and 20% other nonrheumatic diseases. The study shows that the presence of ACA, as detected during routine ANA-testing, does not strongly suggest a diagnosis of CREST at that time. The presence of a scleroderma-variant in almost 50% of the patients and the occurrence of Raynaud's phenomenon in 62% underscores, however, an association of ACA with (early) scleroderma-like disorders.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7835004     DOI: 10.1007/bf02242937

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  38 in total

1.  Positive antinuclear antibodies in malignancies.

Authors:  M Zuber
Journal:  Ann Rheum Dis       Date:  1992-04       Impact factor: 19.103

2.  Drug-induced anticentromere antibody?

Authors:  G Haberhauer; H Bröll
Journal:  Z Rheumatol       Date:  1989 Mar-Apr       Impact factor: 1.372

3.  The diagnostic associations of patients with antinuclear antibodies referred to a community rheumatologist.

Authors:  W C Shiel; M Jason
Journal:  J Rheumatol       Date:  1989-06       Impact factor: 4.666

4.  Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients.

Authors:  E S Weiner; W C Earnshaw; J L Senécal; B Bordwell; P Johnson; N F Rothfield
Journal:  Arthritis Rheum       Date:  1988-03

5.  The analysis of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assays.

Authors:  R J Kipnis; J Craft; J A Hardin
Journal:  Arthritis Rheum       Date:  1990-09

6.  A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report.

Authors:  F E Harper; H R Maricq; R E Turner; R W Lidman; E C Leroy
Journal:  Am J Med       Date:  1982-06       Impact factor: 4.965

7.  The anticentromere antibody: disease specificity and clinical significance.

Authors:  F C Powell; R K Winkelmann; F Venencie-Lemarchand; J L Spurbeck; A L Schroeter
Journal:  Mayo Clin Proc       Date:  1984-10       Impact factor: 7.616

8.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

Review 9.  Antinuclear antibodies (ANAs): diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity.

Authors:  E M Tan; E K Chan; K F Sullivan; R L Rubin
Journal:  Clin Immunol Immunopathol       Date:  1988-05

10.  Anticentromere antibody and primary pulmonary hypertension.

Authors:  J R Seibold; M C Trontell
Journal:  J Rheumatol       Date:  1982 Jul-Aug       Impact factor: 4.666

View more
  4 in total

Review 1.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

2.  Anti-centromere antibody is an independent risk factor for chronic kidney disease in patients with primary biliary cirrhosis.

Authors:  Shintaro Mandai; Eiichiro Kanda; Yohei Arai; Suguru Hirasawa; Toshiyuki Hirai; Shota Aki; Naoto Inaba; Makoto Aoyagi; Hiroyuki Tanaka; Takaaki Ikeda; Teiichi Tamura; Sei Sasaki
Journal:  Clin Exp Nephrol       Date:  2012-12-26       Impact factor: 2.801

3.  Increased prevalence of anti-third generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome.

Authors:  R Wu; O Shovman; Y Zhang; B Gilburd; G Zandman-Goddard; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2007-02       Impact factor: 10.817

4.  Anti-centromere antibody exhibits specific distribution levels among anti-nuclear antibodies and may characterize a distinct subset in rheumatoid arthritis.

Authors:  Nobuo Kuramoto; Koichiro Ohmura; Katsunori Ikari; Koichiro Yano; Moritoshi Furu; Noriyuki Yamakawa; Motomu Hashimoto; Hiromu Ito; Takao Fujii; Kosaku Murakami; Ran Nakashima; Yoshitaka Imura; Naoichiro Yukawa; Hajime Yoshifuji; Atsuo Taniguchi; Shigeki Momohara; Hisashi Yamanaka; Fumihiko Matsuda; Tsuneyo Mimori; Chikashi Terao
Journal:  Sci Rep       Date:  2017-07-31       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.